查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1412528

遺傳性血管水腫治療藥物市場：依藥物類別、治療類型、給藥途徑- 全球預測 2024-2030

Hereditary Angioedema Therapeutics Market by Drug Class (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor, Kallikrein Inhibitor), Treatment Type (On-Demand, Prophylaxis), Route Of Administration - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年遺傳性血管水腫治療市場規模為365.9億美元，2024年達382.9億美元，2030年達551.9億美元，複合年成長率為6.04%。

遺傳性血管水腫治療的全球市場

主要市場統計
基準年[2023] 365.9億美元
預測年份 [2024] 382.9億美元
預測年份 [2030] 551.9億美元
複合年成長率（%） 6.04%
遺傳性血管性水腫治療藥物Market-IMG1

FPNV定位矩陣

FPNV 定位矩陣對於評估遺傳性血管水腫治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對遺傳性血管水腫治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-遺傳性血管水腫治療藥物市場的市場規模和預測是多少？

2-在遺傳性血管水腫治療藥物市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-遺傳性血管水腫治療市場的技術趨勢和法律規範是什麼？

4-遺傳性血管水腫治療藥物市場主要供應商的市場佔有率是多少？

5-進入遺傳性血管水腫治療市場的適當型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球遺傳性血管性水腫病例增加
      • 努力提高人們對疾病激增的認知
      • 遺傳性血管性水腫治療不當
    • 抑制因素
      • 對 HAE 治療藥物藥物的擔憂
    • 機會
      • 遺傳性血管水腫治療的核准增加
      • 潛在重點開發遺傳性血管性水腫的新治療方法
    • 任務
      • 對 HAE 狀況缺乏認知
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章依藥物類別分類的遺傳性血管水腫治療藥物市場

  • 緩激肽 B2 受體拮抗
  • C1-酯酶抑制劑
  • 激肽釋放酶抑制劑

第7章依治療類型分類的遺傳性血管水腫治療藥物市場

  • 一經請求
  • 預防

第8章遺傳性血管水腫治療藥物市場：依給藥途徑

  • 靜脈
  • 口服
  • 皮下的

第9章北美和南美遺傳性血管水腫治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區遺傳性血管水腫治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲遺傳性血管水腫治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • Adverum Biotechnologies, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • Astria Therapeutics, Inc.
    • Attune Pharmaceuticals
    • BioCryst Pharmaceuticals, Inc.
    • BioMarin Pharmaceutical Inc.
    • Centogene NV
    • Cipla Inc.
    • CSL Limited
    • Intellia Therapeutics, Inc.
    • Ionis Pharmaceuticals, Inc.
    • KalVista Pharmaceuticals, Inc.
    • Pharming Group NV
    • Pharvaris GmbH
    • Takeda Pharmaceutical Company Limited
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-742BD517F735

[190 Pages Report] The Hereditary Angioedema Therapeutics Market size was estimated at USD 36.59 billion in 2023 and expected to reach USD 38.29 billion in 2024, at a CAGR 6.04% to reach USD 55.19 billion by 2030.

Global Hereditary Angioedema Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 36.59 billion
Estimated Year [2024] USD 38.29 billion
Forecast Year [2030] USD 55.19 billion
CAGR (%) 6.04%
Hereditary Angioedema Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hereditary Angioedema Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hereditary Angioedema Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hereditary Angioedema Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., Arrowhead Pharmaceuticals, Inc., Astria Therapeutics, Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Centogene N.V., Cipla Inc., CSL Limited, Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Pharming Group N.V., Pharvaris GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Hereditary Angioedema Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Bradykinin B2 Receptor Antagonist
    • C1-Esterase Inhibitor
    • Kallikrein Inhibitor
  • Treatment Type
    • On-Demand
    • Prophylaxis
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hereditary Angioedema Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hereditary Angioedema Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Hereditary Angioedema Therapeutics Market?

4. What is the market share of the leading vendors in the Hereditary Angioedema Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Hereditary Angioedema Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Hereditary Angioedema Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing cases of hereditary angioedema across the globe
      • 5.1.1.2. Surging initiatives to improve the awareness about the disease
      • 5.1.1.3. Inadequate treatment of the hereditary angioedema
    • 5.1.2. Restraints
      • 5.1.2.1. Concern regarding adverse reactions of HAE therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in approvals of hereditary angioedema drugs
      • 5.1.3.2. Potential focus on developing novel therapeutics for hereditary angioedema
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness about HAE conditions
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Hereditary Angioedema Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Bradykinin B2 Receptor Antagonist
  • 6.3. C1-Esterase Inhibitor
  • 6.4. Kallikrein Inhibitor

7. Hereditary Angioedema Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. On-Demand
  • 7.3. Prophylaxis

8. Hereditary Angioedema Therapeutics Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Americas Hereditary Angioedema Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hereditary Angioedema Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hereditary Angioedema Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Adverum Biotechnologies, Inc.
    • 13.1.2. Arrowhead Pharmaceuticals, Inc.
    • 13.1.3. Astria Therapeutics, Inc.
    • 13.1.4. Attune Pharmaceuticals
    • 13.1.5. BioCryst Pharmaceuticals, Inc.
    • 13.1.6. BioMarin Pharmaceutical Inc.
    • 13.1.7. Centogene N.V.
    • 13.1.8. Cipla Inc.
    • 13.1.9. CSL Limited
    • 13.1.10. Intellia Therapeutics, Inc.
    • 13.1.11. Ionis Pharmaceuticals, Inc.
    • 13.1.12. KalVista Pharmaceuticals, Inc.
    • 13.1.13. Pharming Group N.V.
    • 13.1.14. Pharvaris GmbH
    • 13.1.15. Takeda Pharmaceutical Company Limited
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 10. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ B2 RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 144. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET LICENSE & PRICING